SillaJen, Inc. (KOSDAQ:215600)
2,430.00
-100.00 (-3.95%)
Jun 10, 2026, 3:30 PM KST
SillaJen Revenue
SillaJen had revenue of 2.85B KRW in the quarter ending March 31, 2026, with 146.45% growth. This brings the company's revenue in the last twelve months to 10.92B, up 128.38% year-over-year. In the year 2025, SillaJen had annual revenue of 9.23B with 134.94% growth.
Revenue (ttm)
10.92B
Revenue Growth
+128.38%
P/S Ratio
30.83
Revenue / Employee
191.58M
Employees
57
Market Cap
336.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.23B | 5.30B | 134.94% |
| Dec 31, 2024 | 3.93B | -12.90M | -0.33% |
| Dec 31, 2023 | 3.94B | -1.07B | -21.42% |
| Dec 31, 2022 | 5.01B | 4.76B | 1,870.95% |
| Dec 31, 2021 | 254.36M | -1.42B | -84.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Medy-Tox | 244.02B |
| BINEX | 164.00B |
| GC Cell | 163.35B |
| MEDIPOST | 73.90B |
| HLB Therapeutics | 67.56B |
| Anterogen.Co.,Ltd. | 8.06B |
| Genomictree | 3.83B |